| Dec-2024 | Sep-2024 | Jun-2024 | Mar-2024 | Dec-2023 | |
|---|---|---|---|---|---|
Promoter | - | - | - | - | - |
Foreign | 0% | 0% | 0% | 0% | 0% |
Indian | 43.87% | 43.87% | 43.87% | 43.84% | 43.84% |
Total Promoter | - | - | - | - | - |
Institutions | 26.25% | 25.41% | 22.34% | 20.74% | 20.32% |
Non-Institutions | 29.87% | 30.71% | 33.78% | 35.4% | 35.82% |
Total Non-Promoter | 56.12% | 56.12% | 56.12% | 56.15% | 56.15% |
Custodian | 0% | 0% | 0% | 0% | 0% |
Total | 100% | 100% | 100% | 100% | 100% |
The US Food and Drug Administration (FDA) approved the pharmaceutical company's Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
